News | July 22, 2021
Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The study was conducted in patients with mild to moderate COVID-19
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Subscribe To Our Newsletter & Stay Updated
